CNBX Pharmaceuticals (CNBX) Stock Price, News & Analysis

Company Overview

CNBX Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the research and development of synthetic cannabinoid-based drug candidates. The company’s proprietary platform applies medicinal chemistry techniques to design novel small-molecule analogs of naturally occurring cannabinoids, aiming to improve efficacy and safety compared with existing therapies. Its pipeline includes multiple preclinical compounds targeting neuropathic and chronic pain, with a goal of advancing these candidates through IND-enabling studies.

Headquartered in Costa Mesa, California, CNBX Pharmaceuticals collaborates with contract research organizations and academic partners to conduct pharmacology and toxicology studies as well as scale up manufacturing processes. The company has assembled an intellectual property portfolio covering its lead compounds and key synthetic methods, positioning its programs for potential licensing or partnership opportunities that can support late-stage development and commercialization.

CNBX Pharmaceuticals’ management team brings together experts in pharmaceutical chemistry, clinical development and regulatory affairs to guide its programs through critical R&D milestones. As a clinical-stage enterprise, CNBX remains focused on advancing its lead assets toward first-in-human trials and forging strategic alliances to accelerate the delivery of next-generation cannabinoid-based therapies for patients with significant unmet medical needs.

Key Stats

• Today's Range: $0.0001 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0063
• Volume: 46.66 million shs
• Average Volume: 40.93 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CNBX Pharmaceuticals Stock Analysis - MarketRank™

CNBX Pharmaceuticals scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for CNBX Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CNBX Pharmaceuticals is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CNBX Pharmaceuticals is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

CNBX Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CNBX Pharmaceuticals has recently decreased by 2.51%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CNBX Pharmaceuticals does not currently pay a dividend.

Dividend Growth

CNBX Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for CNBX on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CNBX Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

73.51% of the stock of CNBX Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

98.18% of the stock of CNBX Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CNBX Stock Analysis - Frequently Asked Questions

How have CNBX shares performed this year?

CNBX Pharmaceuticals' stock was trading at $0.0004 at the beginning of 2026. Since then, CNBX stock has decreased by 50.0% and is now trading at $0.0002.

When did CNBX Pharmaceuticals' stock split?

CNBX Pharmaceuticals's stock reverse split before market open on Thursday, May 12th 2022.The 1-120 reverse split was announced on Thursday, May 12th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of CNBX Pharmaceuticals?

Shares of CNBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CNBX Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CNBX Pharmaceuticals investors own include Organigram Global (OGI), Green Thumb Industries (GTBIF), Canopy Growth (CGC), Curaleaf (CURLF), Kushco (KSHB) and Trulieve Cannabis (TCNNF).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Cannabis
• Current Symbol: OTCMKTS:CNBX
• CIK: 1343009
• Web: www.cannabics.com
• Phone: (877) 424-2429
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A